Quick Search: Board of Directors Scientific and Medical Advisory Committee RVA Staff
Board of Directors
Rare Voices Australia’s (RVA) Board comprises dedicated and passionate people across Australia. A number of board members have a personal connection with a rare disease. The Board meets regularly and oversees RVA’s strategic direction and purpose.
Dr Carol Wicking
CHAIR, Rare Voices Australia (QLD)
Dr Carol Wicking received her BSc (Hons) and MSc from the University of Melbourne and her PhD from the University of London. She has over 25 years of research experience, primarily investigating the molecular and cellular basis of a number of rare diseases including cystic fibrosis, naevoid basal cell carcinoma syndrome and a class of rare diseases known as ciliopathies. Carol is the Science Advisor and a Board Member of Phenomics Australia, a capability of the National Collaborative Research Infrastructure Strategy. She is currently an independent consultant and an Honorary Associate Professor at the Institute for Molecular Bioscience at the University of Queensland. Carol is also a member of RVA’s Scientific and Medical Advisory Committee.
Andrew Carter
DEPUTY CHAIR, Rare Voices Australia (VIC)
Andrew is the founder of Commercial Eyes Pty Ltd and has over 30 years’ experience working in the health technology industry. Headquartered in Melbourne and employing over 110 people, Commercial Eyes has grown to be one of the foremost commercialisation firms in Australia. In addition to Andrew’s leadership and industry experience, he is a highly qualified and skilled company director, with over 20 years of governance experience in the private and not-for-profit sectors. He is passionate about social justice and an active volunteer in a range of community support programs. Andrew is a member of the University of Melbourne Master of Biotechnology Advisory Council, and past Chair and non-executive director of a variety of not-for-profit organisations including ARCS, BioMelbourne Network, Melbourne City Mission and Whitley College. He has a Bachelor of Science, Graduate Diploma of Business, Master of Commercial Law and is a member of the Australian Institute of Company Directors (AICD).
Joanna Betteridge
Director, Rare Voices Australia (VIC)
Joanna Betteridge, Principal of Betteridge Legal Consulting, is an employment and workplace safety lawyer and consultant and an accredited mediator. Joanna is also a Senior Fellow at Monash University and lectures in its Law Faculty post graduate program including lecturing in anti-discrimination law. Joanna is the immediate past Chair of the TEAR Australia Board (a global aid and development organisation) and has held a number of Board roles in a variety of not-for-profit and Government Boards since 2003. Joanna sat for many years on the committee of the Australian MPS Society, becoming involved soon after her two nephews, Jack and Tom, were diagnosed with MPS III, Sanfilippo Syndrome, in 1998.
Kate Henderson
Director, Rare Voices Australia (QLD)
Kate is a non-executive director with a passion for ethics, mental health and data management and security. She is a Human Research Ethics Committee member at both the University of Queensland (UQ) and Queensland Health’s Forensic and Scientific Services, is a member of UQ’s Ethics Advisory Group, and is also Chair of the Governance, Risk and Ethics Committee at Making Good Alliance. Kate has been working with Beyond Blue for over four years as a Project Steering Committee member for two of their national programs, Be You and The Way Back Support Service. She has a background in the disability sector and spent many years as Business Process and Information Manager for a large public sector organisation. In 2012, Kate was diagnosed with Fibromuscular Dysplasia, a vascular disease that leads to narrowing, dissection or aneurysm of medium-sized arteries.
Prof Eric Morand
Director, Rare Voices Australia (VIC)
Professor Eric Morand is Professor and Head of the School of Clinical Sciences at Monash Health, Monash University’s largest clinical school. He is also a specialist rheumatologist, and Head of the Monash Health Rheumatology Unit, the largest in Australia. He specialises in research and clinical care of systemic lupus erythematosus (SLE), as well as complex rheumatic diseases and rheumatoid arthritis. He is the founder of the Monash Lupus Clinic, Australia's largest research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the Asia Pacific Lupus Collaboration.
Viswanathan Narayanaswamy (Vishy)
Director, Rare Voices Australia (NSW)
Viswanathan Narayanaswamy (Vishy) is a Chartered Accountant by profession with extensive experience in audit and accounting advisory for over 20 years in India and Australia. Vishy is a member of the Institute of Chartered Accountants of Australia and New Zealand and the Institute of Chartered Accountants of India. He is also a member of The Tax Institute and is a registered tax agent with the Tax Practitioners Board. He is currently working with PwC in their Accounting Consulting Services team. Vishy leads all of Rare Voices Australia’s (RVA) accounting, financial and tax-related matters and helps the RVA Board in complying with all regulatory requirements. Vishy was diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) disease, a rare blood disorder, in 2008 and has been receiving treatment since. He is also a board member with Sydney Blood Cancer Research Institute, which provides laboratory and clinical research for haematology patients.
Teresa Pilbeam
Director, Rare Voices Australia (QLD)
Teresa Pilbeam is a special education teacher, an advocate for informal family carers and has worked alongside Aboriginal and Torres Strait Islander people across Australia. Teresa has 30 years’ experience in special education, contributed to carer and disability reform for over 10 years, is an independent director on government and profit-for-purpose state and federal councils and boards, and has a lived experience of autism spectrum and complex disability. Teresa brings experience and expertise of governance, ways of working with Aboriginal and Torres Strait Islander people, and an enthusiasm for enabling the voice of informal family carers to be heard in cross-sector conversations.Scientific and Medical Advisory Committee
RVA’s Scientific and Medical Advisory Committee (SMAC) provides the organisation with medical and clinical perspectives, guidelines and information as needed.
SMAC Terms of Reference (PDF)
Prof Adam Jaffé
CHAIR, UNSW/Sydney Children’s Hospital, Randwick, Respiratory Disorders, CF, Consumers, Clinicians & Clinical Trials (NHMRC) (NSW)
Professor Adam Jaffé is the John Beveridge Professor of Paediatrics and Head of the Discipline of Paediatrics and Child Health and Clinical Campus, Randwick School of Clinical Medicine, UNSW Medicine, and a Paediatric Respiratory Consultant at Sydney Children’s Hospital, Randwick. Professor Jaffé was appointed as Consultant in Paediatric Research at Great Ormond Street Hospital for Children and headed up respiratory medicine research at the Institute of Child Health London in 2001 until moving to Australia in 2006. Adam chairs the Young Lungs program of Lung Foundation Australia and is on Lung Foundation Australia’s Rare Lung Diseases Committee. He is chair of RVA’s Scientific and Medical Advisory Committee and is on the Board (ex officio). He is on the boards of Children’s Cancer Institute and the Australian Institute of Health Innovation. He is the Chair of the Research Advisory Committee of Asthma Australia. He was on the advisory committees for the National Strategic Plan for Lung Conditions (2019) and the National Strategic Action Plan for Rare Diseases (2020).
Clin/Prof Gareth Baynam
Rare Care Centre, Western Australian Register of Developmental Anomalies, GSWA, WADoH, Centres of Expertise, Phenotyping, Digital Health (WA)
Professor Gareth Baynam is the Medical Director of the Rare Care Centre and its state-wide clinical service based at the Perth Children’s Hospital; Head of the Western Australian Register of Developmental Anomalies (birth defects and cerebral palsy registers); Clinical Geneticist and Program Director of the Undiagnosed Diseases Program WA; Foundation Board Member of the Undiagnosed Diseases Network International; and Adjunct Genomics Policy Officer in the Western Australian Health Department. He is affiliated with the University of Western Australia; Curtin University; Murdoch University; Notre Dame University; Melbourne University; and Telethon Kids Institute. He is the founder of an integrated suite of cross-sector and community engaging initiatives to improve the lives of people living with rare diseases including Project Y, Cliniface (3D facial analysis for rare diseases diagnosis, clinical trials and device design) and Lyfe Languages (Universal Indigenous Medical Translator). He has partnered with the Aboriginal health care leaders and communities in WA over more than a decade to implement a range of state-wide initiatives to improve the equity for Indigenous people living with rare diseases. He Chairs and/or is one of the Executive or Advisories of multiple international rare diseases initiatives; and multiple National Institutes of Health in Europe, North America and Asia. He has personal connections to rare diseases.
Dr Kaustuv Bhattacharya
Metabolic Paediatrician, Genetic Metabolic Disorders Service (NSW); Conjoint Senior Lecturer, University of Sydney (NSW)
Dr Bhattacharya performed undergraduate medical training at the University of London. His post graduate MD (res) at the University of London involved investigator-led clinical trials conducted at The National Hospital for Neurology and Neurosurgery and Great Ormond Street Hospital for Children in London. He has published novel approaches to treatment of glycogen storage disease type I, HMG Co-A Lyase deficiency, fat oxidation disorders, Hunter syndrome and Aspartylglucosaminuria. He has been in Australia since 2008 working as a full-time metabolic specialist. He is currently president of the Australasian Society of Inborn Errors of Metabolism (ASIEM).
Dr Lisa Ewans
Clinical Geneticist (NSW); Conjoint Senior Lecturer, University of New South Wales Sydney; Research Officer, Garvan Institute of Medical Research
Dr Lisa Ewans is a Clinical Geneticist at Sydney Children’s Hospitals Network (SCHN) Randwick and a post-doctoral Research Officer at the Genomics and Inherited Disease Program at the Garvan Institute of Medical Research. Dr Ewans specialises in diagnosing and supporting individuals with, or at risk of, genetic conditions throughout the lifespan. Her research focuses on improving diagnosis for rare disease through genomics and novel methods and translating these to the clinic to improve patient outcomes. She co-manages a rare disease registry at SCHN and is helping to establish an SCHN undiagnosed disease program as well as understanding and improving the value of genetic services to the rare disease community.
Prof Lynn Gillam AM
Clinical Ethicist; Academic Director of the Children’s Bioethics Centre at the Royal Children’s Hospital Melbourne (VIC)
Lynn is a Clinical Ethicist and Academic Director of the Children’s Bioethics Centre at the Royal Children’s Hospital Melbourne. Lynn provides clinical ethics case consultation, policy advice and leads research in paediatric clinical ethics. She is also Professor in Health Ethics at the University of Melbourne, in the Department of Paediatrics, where she teaches ethics and qualitative research design in the MD and other health professional courses.
A/Prof Paul Lacaze
U Monash U/Alfred, Genomics, Cohort Studies, Biobanking, Rare Disease Registries (VIC)
Dr Paul Lacaze is a geneticist and Head of Public Health Genomics at Monash University. He conducts research into the role of genetic data in public and population health, through large-scale cohort studies, biobanks, clinical trials, and registries. He leads genomics for the ASPREE study, Australia’s largest clinical trial and study of healthy ageing in >15,000 Australians and works with the Monash Registries Science Unit in the area of rare disease registries. He conducts research into the ethical, legal and social issues associated with the use of genomic information in society. He founded the Australian Non-Genetic Discrimination Working Group, a national body advocating for regulatory change around the use of genetic test results in life insurance. He is passionate about developing a National Plan and Alliance for Rare Disease Registries in Australia.
Dr Kristen Nowak
Director, Office of Population Health and Genomics, WA Department of Health (WA)
Dr Kristen Nowak has over 20 years’ experience as a medical researcher in the rare diseases field, focusing on finding new disease genes and evaluating potential therapies. Her office has a strong focus on the translation of evidence-based genomic and screening technology into the health system, and a longstanding emphasis on improving the healthcare journey of people with rare diseases. Kristen is a member for the Standing Committee on Screening, and the Project Reference Group on Health Genomics. She is also chair of the national Newborn Bloodspot Screening Program Management Committee. Kristen is an Honorary Research Fellow at the Harry Perkins Institute of Medical Research and an Adjunct Senior Lecturer at the University of Western Australia.
Dr (Elizabeth) Emma Palmer
Clinical Geneticist, Sydney Children’s Hospitals Network; University Lecturer, University of New South Wales (NSW)
Dr (Elizabeth) Emma Palmer is a university lecturer at the University of New South Wales in Sydney, Australia, and Clinical Geneticist at Sydney Children's Hospitals Network. Dr Palmer is passionate about improving the patient journey for all with rare genetic conditions and their families. Her work aims to improve the recognition of the possibility of genetic conditions by improving clinician education about rare diseases, maximising the diagnostic yield of genetic tests and optimising patient care by linking families to best practice guidelines, treatments and supports. Dr Palmer strives to ensure that the patient and family voice is always central to all her research. She has over 100 peer reviewed journal articles, including those describing nine new genetic conditions.
Prof John Rasko
Director, Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital and the Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney (NSW)
Professor John Rasko is an Australian pioneer in the application of adult stem cells and genetic therapy, and President (2018-20) of the International Society for Cell & Gene Therapy. He is a clinical haematologist, pathologist and scientist with an international reputation in gene and stem cell therapy, experimental haematology and molecular biology. In over 170 publications he has contributed to the understanding of stem cells and blood cell development, gene therapy technologies, cancer causation and treatment, human genetic diseases and molecular biology. John has served on a number of hospital, state and national bodies. He is the recipient of national and international awards in recognition of his commitment to excellence in medical research, including appointment as an Officer of the Order of Australia.
Ann Single
Coordinator, Patient Voice Initiative, Health Technology Assessment international Vice-President, Patient and Citizen Involvement Interest Group Outgoing Chair (QLD)
Ann Single is the Coordinator for the Patient Voice Initiative. She’s worked in patient involvement in health technology assessment (HTA) for more than 20 years, first directing it and in communication within Scotland’s HTA agency and then sharing and developing good practice in Health Technology Assessment international’s (HTAi) Patient and Citizen Involvement Interest Group (PCIG). Chair of this group from 2019-2023, Ann now is PCIG Outgoing Chair and HTAi Vice-President, the first from the patient community sector. Ann co-edited the only book on patient involvement in HTA (version two due June 2025), is a faculty member of the International Patient Advocacy Management Masters Course at Rome’s Catholic University (Università Cattolica del Sacro Cuore) and has most recently published on patient involvement in HTA governance and process development. She served as a consumer representative on the Australian Government’s HTA Policy and Methods Review Reference Committee (due May 2024).
Dr Jane Tiller
Ethical, Legal & Social Adviser in Public Health Genomics, Monash University, Co-founder, Australian Genetic Non-Discrimination Working Group, Co-lead, DNA Screen (VIC)
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher who is passionate about increasing equitable access to genomic medicine for public health outcomes. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University and co-founded the Australian Genetic Non-Discrimination Working Group. Jane led a project from 2020-2023 about genetic discrimination in life insurance and continues to work towards policy outcomes in this area. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population.
RVA Staff
RVA’s staffing team is dedicated to working towards the best outcomes for Australians living with a rare disease.
Nicole Millis
Chief Executive Officer (VIC)
Nicole was appointed Chief Executive Officer of RVA in June 2016. An experienced social worker, she has both personal and professional experience in the rare disease sector. Nicole has engaged in systemic rare disease advocacy since 2008 and has extensive experience regarding access to treatments. Since 2018, Nicole has held the role of consumer nominee on the Life Saving Drugs Program Expert Panel. In 2023, Nicole accepted a health technology assessment appointment to the Enhanced Consumer Engagement Process Co-design Group as a consumer member. Under Nicole’s guidance, RVA led the collaborative development of the National Strategic Action Plan for Rare Diseases, the first nationally coordinated effort to address rare diseases in Australia.
Louise Healy
Education and Advocacy Manager (QLD)
Louise has extensive experience working as a consultant and coach in the corporate sector and has post graduate qualifications in psychology. Her connection with rare conditions began when her first child was born with a rare metabolic disorder. Louise has been involved in rare disease support and advocacy for over 10 years and she is the current Vice President of the Metabolic Dietary Disorders Association (MDDA). She has led successful advocacy campaigns for access to medicines and support programs for people with rare disorders of protein metabolism. Louise is a previous RVA Board member, current member of the Queensland Genomics Community Advisory Board and a founding board member of the Global Association for PKU.
Fiona Lawton
Disability Advocacy Manager (QLD)
Fiona has over 25 years of experience working as a senior manager in the government sector across community and stakeholder engagement, safety and risk management, and training. She has a science degree specialising in neurology and post graduate qualifications in psychology. Fiona has a son who lives with Angelman syndrome, a rare monogenic neurodevelopmental disorder and has actively engaged in rare disease support and advocacy for over 15 years. She is the current President of the Angelman Syndrome Association Australia (ASAA) and was a founding board member of Foundation for Angelman Syndrome Therapeutics (Australia) in 2010. Fiona is a passionate disability advocate and health consumer representative for people with rare disease and complex disability. She currently sits on the Standing Committee for the National Patient Organisation Network (Australia) and Intellectual Disability Peak Working Group, led by Down Syndrome Queensland.
Sarah Cannata
Communications Manager (VIC)
Sarah is a qualified journalist and has over 10 years’ worth of experience working in communications. In addition to publishing a picture book, Sarah has been published in 'The Huffington Post', 'Elephant Journal', 'Mamamia', 'The Age', 'Women's Agenda', 'SBS Online' and more. Sarah has extensive experience across a range of sectors, particularly in the not-for-profit space. She is dedicated to using her skills to benefit Australians living with a rare disease.
Dr Falak Helwani
Research and Evaluation Manager (QLD)
Falak is a former research scientist with a PhD in molecular cell biology from the University of Queensland and postdoctoral experience in hematopoietic stem cell and bone marrow transplant biology at the Mater Medical Research Institute. She has co-authored several publications and has presented her research both in Australia and overseas. Falak paused her research career to care for her daughter who has a rare congenital heart defect and later learned that her youngest son has a rare auto-inflammatory disease. As RVA’s Research and Evaluation Manager, Falak is committed to ensuring that evidenced-based understanding of rare disease drives advocacy and policy reform.
Anne Hunter
Executive Assistant to the Chief Executive Officer, Administrative Manager (VIC)
Anne works for RVA as our Administrative Officer and is based in Victoria. Anne has a personal connection with rare disease and lives with Fabry Disease. She also cares for a child living with Fabry Disease. Anne is on the Fabry Australia committee.
Malcolm Fung
Finance and Compliance Manager (VIC)
Malcolm has worked in the not-for-profit sector in Australia and internationally since 2001. This has included roles with organisations working with people with disabilities and other vulnerable communities in developing countries. His background is in internal auditing, risk management and operations. Malcolm has a personal connection with a rare disease and this has motivated him to use his skills and experience to contribute to RVA’s work.
Dr Amanda Choo
Resources and Information Officer (SA)
Amanda comes from a background in scientific research, having graduated with a PhD in Sciences (in the area of Genetics) from the University of Adelaide. She has previously worked on research projects studying Mucopolysaccharidosis Type III (MPS III, Sanfilippo Syndrome) and the tumour suppressor gene WW domain containing oxidoreductase (WWOX). Amanda has also worked as a University tutor for Medical Genetics. Since then, she has gone on to lead projects on developing genetic technologies for the horticultural sector, all whilst maintaining an active interest in human genetics. Amanda has a personal connection with rare disease, living with myasthenia gravis, and is passionate about using her scientific skills and knowledge to develop and provide customised, evidence-based information about rare diseases for the rare disease community.
Jess Brooklyn
Education Project Officer (WA)
Jess brings a wealth of experience from the youth work and tertiary education sectors. A qualified sociologist, Jess has always sought to help others through grass-roots movements, advocacy and building capacity through education. After more than 20 years seeking medical help for their condition, Jess was diagnosed with Ehlers-Danlos Syndrome in 2020. Jess is very passionate about promoting awareness and understanding so that others can avoid diagnostic delays and obtain the support required when living with a rare disease.
Evelyn Loh
Communications and Information Officer (VIC)
Evelyn comes from a background in clinical trials and healthcare marketing. She holds a Bachelor of Biomedicine and has experience in cancer research. In her previous roles, Evelyn led patient recruitment and communication efforts, coordinating multiple dermatology phase 1-4 clinical trials. Her close interaction with people has provided a deep understanding of the challenges they face in accessing clinical care and treatment. Evelyn is passionate about raising awareness and providing resources through effective science communication and content creation. She is excited to contribute her diverse skillsets and enthusiasm for marketing to drive improved outcomes for the rare disease community.
